Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis

Eroğlu, Aydan; Kurtman, Cengiz; Ulu, Arzu; Çam, Ragıp; Akar, Nejat

doi:10.1111/j.1538-7836.2005.01346.x

Cited by 13 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various Turkish studies had shown that FVL mutation was higher in cancer patients with VTE (30%) compared to patients without VTE (5.8 and 3.7, respectively) [19,20]. In 2009, Eroglu et al [9] revealed similar findings.…”

Section: Discussionsupporting

confidence: 51%

Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients

Wahba

Ismail²,

Saad³

et al. 2015

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a common complication in cancer patients. Several genetic risk factors related to thrombophilia are known; however, their contributions to thrombotic tendency in cancer patients have conflicting results. We aimed to determine the prevalence of factor V Leiden (FVL), prothrombin (PTH) G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphisms in Egyptian nonmetastatic cancer patients and their influence on thrombosis risk in those patients. Factor V Leiden, PTH G20210A and MTHFR C677T polymorphisms were detected in 40 cancer patients with VTE (group 1) and 40 cancer patients with no evidence of VTE (group 2) by PCR-based DNA analysis. Factor V and MTHFR mutations were higher in group 1 than in group 2 (factor V heterozygous mutation: 20 vs. 7.5%, homozygous mutation: 10 vs. 2.5%; MTHFR heterozygous mutation: 40 vs. 25%, homozygous mutation 5 vs. 0%, respectively) (P = 0.03). Mortality rate was higher in group 1 (75%) than in group 2 (25%; P < 0.001). No difference was found between those groups regarding PTH mutation (P = 1). Mortality rate was higher in the presence of homozygous and heterozygous factor V mutation (100 and 82%, respectively) compared to the wild type (41%) (P = 0.0006). Having any of the three studied gene mutations worsened the overall survival (P = 0.0003). Cox regression proved that both thrombosis and presence of factor V mutation are independent factors affecting survival in cancer patients (P < 0.001 and P = 0.01, respectively). In conclusion, there is an association between factor V and MTHFR mutations and risk of VTE in Egyptian cancer patients. Thrombosis and presence of factor V mutation are independent factors that influence survival in those patients.

show abstract

Section: Discussionsupporting

confidence: 51%

Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients

Wahba

Ismail²,

Saad³

et al. 2015

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…These mutations were determined by using commercially available the LightCycler-FVL and prothrombin (G20210A) mutations detection kits (Roche Diagnostics GmbH, Roche Molecular Biochemicals, Mannheim, Germany), respectively [13,16].…”

Section: Methodsmentioning

confidence: 99%

“…Likewise, additional presence of acquired and genetic risk factors, such as FVL and PT G20210A mutations, may increase the risk of TE. Although FVL and PT G20210A have been identified as the most common inherited risk factors for TE, studies on the association of these polymorphisms with cancer-associated TE have conflicting results [6][7][8][9][10][11][12][13][14][15]. We have therefore investigated the prevalence of FVL and PT G20210A polymorphisms in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control.…”

Section: Introductionmentioning

confidence: 96%

Prevalence of Factor V 1691 G–A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Eroğlu

Ulu

Çam

et al. 2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

“…We have recently reported that FVL was associated with an increased risk of DVT in cancer patients [9]. In the present study, we have evaluated whether the presence of polymorphism 4G/5G of PAI-1 gene could be an independent risk factor for thrombosis and its relation to FVL was also investigated in adult cancer patients suffering from DVT.…”

mentioning

confidence: 99%

“…Amplified 98/99-bp product was digested with Bse LI (Fermentas, Vilnius, Lithuania) at 55 • C and subjected to 8% polyacrylamide gel electrophoresis. FVL was determined according to the previously reported technique [9].…”

mentioning

confidence: 99%

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis

Eroğlu

Ulu

Akar

2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis

Cited by 13 publications

References 8 publications

Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients

Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients

Prevalence of Factor V 1691 G–A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis

Contact Info

Product

Resources

About